Trastuzumab Deruxtecan for Residual HER2+ Early Breast Cancer
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- these findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
what Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. the trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated important weight loss, the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. However, it’s crucial to note that the trial did *not* show a statistically significant increase in all-cause mortality. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Cardiovascular Death, MI, stroke) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.0 | 2.5 | 1.20 |
| Nonfatal Myocardial Infarction | 3.7 | 2.5 | 1.48 |
| Nonfatal Stroke | 1.5 | 1.1 | 1.36 |
Who is Affected? Understanding Patient Risk
these findings primarily impact individuals with obesity *and* pre-existing cardiovascular disease. This includes those with a history of heart attack, stroke, peripheral artery disease, or other established cardiovascular conditions. The trial did *not* include patients with type 2 diabetes, raising questions about whether the cardiovascular risk profile differs in that population.individuals without pre-existing heart disease likely face a different risk-benefit calculation.
It’s important to emphasize that this doesn’t mean everyone on Ozempic is at risk. The increased risk was observed in a specific subgroup. Though, it underscores the need for a thorough cardiovascular risk assessment *before* initiating semaglutide treatment, particularly in vulnerable populations.
Why this Matters: Beyond Weight Loss
Semaglutide, initially developed for type 2 diabetes, gained widespread popularity for its dramatic weight loss effects. The initial enthusiasm was fueled by studies suggesting potential cardiovascular benefits, particularly in diabetic patients. The SELECT trial challenges this narrative, at least for those with established heart disease. This highlights the complexity of these medications and the importance of considering the entire clinical picture, not just weight loss.